Cognition Therapeutics

CGTX

Biotechnology · Healthcare

Price

$0.96

+0.02 (+2.21%)

Market Cap

$70.7M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+227.3% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 22.2M (2021) → 72.8M (2025)

Cognition Therapeutics is a small biotech company focused on developing drugs to treat diseases that damage the brain and eyes. Its lead drug candidate, CT1812, is being studied as a potential treatment for Alzheimer's disease and dementia with Lewy bodies. The company does not yet sell any products — it is in the clinical trial stage, testing whether its experimental medicines are safe and effective.

Cognition Therapeutics makes no revenue today and funds its research through grants, including support from the National Institutes of Health, and by raising money from investors. It operates primarily in the United States and, with a market cap of around $100 million, is a very small company by industry standards. The biggest risk it faces is clinical failure — if CT1812 does not prove effective in ongoing trials, the company would need to raise more cash or could run out of funding entirely.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+63.4% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$37M/ year

↓ Declining (-11% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

19.6%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~17 months

$31M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-29.2%

Weak — -29.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.01

Conservative — low debt load (0.01)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial